Exelixis, Inc. (EXEL)
After hours:
| Previous Close | 20.91 |
| Open | 20.94 |
| Bid | 21.05 x 600 |
| Ask | 21.09 x 1000 |
| Day's Range | 20.87 - 21.21 |
| 52 Week Range | 18.64 - 24.34 |
| Volume | |
| Avg. Volume | 2,278,650 |
| Market Cap | 6.135B |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | 32.40 |
| EPS (TTM) | 0.65 |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.55 |
Business WireExelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
ALAMEDA, Calif., May 20, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla). This settlement resolves two patent litigations brought by Exelixis in response to Cipla’s Abbreviated New Drug Application (ANDA) seeking approval to market generic versions of CABOMETYX® (cabozantinib) tablets prior to the expiration of the applicable patents. The first case (Civil Action N
Business WireExelixis to Webcast Fireside Chats as Part of Investor Conferences in May
ALAMEDA, Calif., May 07, 2024--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May:
ZacksExelixis (EXEL) International Revenue Performance Explored
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
